ANALYZING THE ROLE OF C-REACTIVE PROTEIN IN CARDIAC PATIENTS WITH UNSTABLE AND STABLE ANGINA
Abstract
Background and objectives: Unstable angina is one of leading causes of hospital admissions for acute coronary disease, which accounts for >30% of admissions for acute myocardial infarction. This study was done to estimate the C-reactive protein level (CRP) as a marker of acute inflammation in patients with unstable and stable angina & to determine the prognostic value of CRP in coronary syndrome.
Methods: A case control study was done including 40 cases of stable angina/control group (attending OPD) and 40 patients unstable angina/study group who are admitted to Intensive coronary care unit. Cases were selected according to inclusion and exclusion criteria in a prescribed Proforma. CRP estimation was done twice in study group and once in control group by latex agglutination method.
Results: The study shows sex ratio 5:1 with maximum presentation between 4th to 6thdecade with mean age of 53.1 years. In study group (unstable angina) CRP levels were elevated in 29 (72.5%) and 12(30%) in control (stable angina) group. Second sample was taken on 7th day of illness in study group; persistent elevated CRP levels were maintained in 7(17.5%) patients.
Conclusion: Raised levels of CRP shows an evidence of growing inflammation at the coronary plaque and persistent elevated CRP levels in patients with unstable angina may indicate persistent instability of the disrupted plaque and is strongly related to the occurrence of subsequent ischemic complications. Serial evaluation of CRP plasmatic concentration may help in assessing the future ischemic events and thus help in preventing complications.
Downloads
References
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349: 1269e1276.
3. Salazar J, Martinez MS, Mervin Chavez M, and Toledo A, Anez R, Yaquelín Torres Y, et al. C-reactive protein: clinical and epidemiological perspectives. Cardiol Res Pract 2014; 2014: 605810. http://dx.doi.org/10.1155/2014/605810
4. Yousuf O, Bibhu D, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, et al. Highsensitivity C-reactive protein and cardiovascular disease. A resolute belief or an elusive link? JACC 2013; 62 (5):397–408.
5. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH,Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysisin Myocardial Infarction J Am CollCardiol1998; 31:1460-1465.
6.. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incrementalprognostic value of C-reactive protein and Nterminalpro B-type natriuretic peptide in acute coronary syndrome. Circ J2006; 70: 1379-1384.
7. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, Verret B, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am CollCardiol;2008: 51: 2339-2346.
8. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122(25):2748–64..
9. Bahl VK, Prabhakaran D, Karthikeyan S. Coronary artery disease in Indians. Indian Heart J, 2001; 53: 707-13.
10. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 2010;21:1064–70.
11. Cachofeiro V, Miana M, Heras N, Martin-Fernandez B, Ballesteros S, Balfagon G, et al. Inflammation: a link between hypertension and atherosclerosis. Curr Hypertens Rev 2009; 5:40–8.
12. Ridker PM. High sensitivity C-reactive protein: potential adjuvant for global risk assessment in the primary prevention of cardiovascular disease. Circulation.
2001;103:1813e1818.
13.Ridker PM, Rifai N, Rose, et al. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557e1565.
14. Ridker P. Clinical application of Creactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363 e 369.
15. Yeh E, Willerson J. Coming of age Creactive protein. Using inflammation markers in cardiology. Circulation. 2003;107: 370e372.
16. Susanne B Schwedler, Kerstin Amann, Konstanze Wernicke, Alexander Krebs, Matthias Nauck, Christopher Wanner et al. Native CRP increases wheras modified CRP reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005;112:1016-23.
17.Amanullah Safiullah, Jarari Abdulla, Govindan Muralikrishnan, Ismail Basha Mohamed, Khatheeja Saira. Association of hs-CRPwith diabetic and non-diabetic
individuals. Jordan J Biol Sci. January 2010;3:7e12.
18. Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactiveprotein, and risk of future cardiovascular events. Circulation.2003;108:2993e2999.
19. Yanbaeva DG, Dentener MA, Creutzber EC, et al. Systemic effects of smoking. Chest. 2007;131:1557e1566.
20. Han T, Sattar N, Williams K, GonzalezVillalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002; 25: 2016 e 2021.
